Navigation Links
Anesiva Announces Second Quarter 2008 Financial Results and Update
Date:8/7/2008

conduct training sessions for selected healthcare providers to advocate for better venous access pain management for their pediatric patients, to grow membership in RNVoice, and to experience increased visits to http://www.manageivpain.com."

-- The FDA accepted Anesiva's electronic sNDA filing to expand the Zingo

label indication to include adults. Under the Prescription Drug User

Fee Act (PDUFA), the agency is expected to make a decision regarding

approval by January 2009.

-- The journal Pediatrics published full results of one of the two pivotal

Phase 3 pediatric trials of Zingo.

-- Anesiva signed an exclusive Zingo licensing and distribution agreement

with Green Vision Company for territories in the Middle East, and

expanded the territories covered under the license and distribution

agreement with Sigma Tau SpA to include most of Europe.

Adlea

-- During the second quarter, Phase 3 enrollment began in a trial of Adlea

for the management of acute pain following total knee replacement

surgery. This multicenter, double-blind, placebo-controlled study will

evaluate the efficacy and safety of a single dose of Adlea or placebo

administered prior to closure of the surgical wound. Total planned

enrollment is 214 patients. Enrollment continued in a 300 patient Phase

3 trial of Adlea in patients undergoing bunionectomy surgery.

-- Anesiva initiated a Phase 2 trial with Adlea for the management of

acute pain following arthroscopic shoulder surgery. Total planned

enrollment in this multicenter, double-blind, dose-escalation, placebo-

controlled trial is 74 patients.

-- Several Adlea posters will be presented at the upcoming World Congress

on Pain, a major international meeting to be held August 17-22, 2008.


'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014 Pfanstiehl ... Mannose (USP/NF, EP), manufactured in the ... "Mannose has long been recognized for playing a ... a growing body of evidence that media supplementation ... consistency of protein glycosylation," according to Dr. ...
(Date:10/1/2014)... (PRWEB) September 30, 2014 Today ... initial round of grants for the Brain Research ... that aims to develop and revolutionize new methods ... of the human brain. This first round of ... year 2014 was allocated to more than 100 ...
(Date:10/1/2014)... September 30, 2014 Award winning ... announces four new-hosted collaboration bundles that combine ... high quality conferencing experiences for low, flat rate ... choose from, businesses have optimized solutions to meet ... include audio only minutes (1K, 5K, 10K ...
(Date:10/1/2014)... October 01, 2014 The U.S. Department ... Southern Illinois University Edwardsville as part of the Trade ... The funding is co-administered by the Department of Labor ... Secretary of Labor Thomas E. Perez and Secretary of ... in job-driven training grants to nearly 270 colleges across ...
Breaking Biology Technology:Pfanstiehl Launches cGMP-produced Mannose for Cell Culture Media Optimization & Glycoprotein Biosynthesis 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3SoundConnect Launches New Audio, Web and Video Bundles 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4
... Clinical Study Demonstrates Breakthrough Dose-Sparing Formulation,That Increases Stockpile ... Doses in a Pandemic Situation Sanofi pasteur, ... showing that its new investigational H5N1 pandemic influenza,vaccine ... response,at the lowest dose of H5N1 antigen reported ...
... often deal with the same problems, but they use ... can be difficult, if not impossible., A new $2.9 ... the National Science Foundation (NSF), will help bridge this ... solve common problems a range of scientists face., The ...
... 17 DaVita Inc.,(NYSE: DVA ) today announced ... Conference in London on Thursday, September 20, 2007 at ... access the live webcast, go to http://www.ibb.ubs.com, ... page, followed by the webcast link,listed next to the ...
Cached Biology Technology:Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage 2Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage 3Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage 4Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage 5CCMR gets $2.9M for training grad students in nanoscale science 2
(Date:10/2/2014)... SHELTON, Conn. , Oct. 2, 2014 NXT-ID, ... focused on the growing mobile commerce market, announces the airings ... Money and Mad Money. The national ads resumed ... will air October 2 nd and October 3 rd ... The continuing ads that began airing on CNBC ...
(Date:10/1/2014)... take a healthy salad up a level by growing ... in leafy greens. , "In the long run, one ... the salad or making a pill from the plant ... at Case Western Reserve School of Medicine and leader ... cancer organization is funding the research with a three-year, ...
(Date:9/30/2014)... tourists visit the Mediterranean each year, but its ... on Earth. Almost 1,000 alien species, including fish, ... seas through human activities. In the open-access journal ... team of researchers analyzed data from a new ... show how the introduction of alien species has ...
Breaking Biology News(10 mins):CNBC Commercial Airings for Wocket Smart Wallet October 2nd and 3rd 2CNBC Commercial Airings for Wocket Smart Wallet October 2nd and 3rd 3Scientists wield plant viruses against deadly human disease 2Scientists wield plant viruses against deadly human disease 3Biodiversity in the Mediterranean is threatened by alien species 2
... forms from solution is a problem that has occupied ... (TU/e), together with researchers from Germany and the USA, ... of crystal formation, which occurs widely in nature and ... years, but is saved now. The team made this ...
... known that horses show symptoms of stress when ridden but ... their riders. This is surprising, as equestrian sports rely ... How does the horse-rider team cope with the stress ... has now been studied by Mareike von Lewinski in the ...
... 2013 Raman spectroscopy has enabled incredible advances ... tool for tissue classification and disease recognition, although ... method in a clinical setting. Scientists have now ... the door to wider biomedical and clinical applications ...
Cached Biology News:Theory of crystal formation complete again 2Theory of crystal formation complete again 3Horses don't have stage fright -- but their riders do 2Breakthrough study opens door to broader biomedical applications for Raman spectroscopy 2
Profilin-1/2 (FL-140)...
Immunogen: Synthetic peptide: N(171) H G F L S A D Q QL I K(183) Storage: -20 C, Avoid Freeze/Thaw Cycles...
The pCDF Expression System 1 plus Competent Cells contains 10 µg of pET-45b(+) DNA. pET-45b carries an N-terminal His•Tag ® coding sequence that is cleavable with enterokinase as well...
HIV-1 TAT (vN-21)...
Biology Products: